Studies evaluating the clinical relevance of MCL1 in PCa have demonstrated MCL1 to be upregulated in response to current PCa therapies (including androgen deprivation therapy, ARSI and taxane chemotherapy), highly expressed in CRPC, and gene copy number gains to be associated with worse clinical outcome.6 The gene discussed is MCL1; the disease is posterior cortical atrophy.